

## Supplementary Data

Table S1: In vitro antimicrobial susceptibility tests showing susceptible results for 121 *Nocardia* isolates from solid organ transplant recipients

	<b>Susceptible (N = 121)</b>
Amikacin	113 (93.4)
Amoxicillin-clavulanate	49 (40.5)
Cefepime	28 (23.1)
Ceftriaxone	40 (33.1)
Ciprofloxacin	32 (26.4)
Clarithromycin	50 (41.3)
Doxycycline	20 (16.5)
Imipenem	86 (71.1)
Linezolid	121 (100)
Minocycline	40 (33.1)
Moxifloxacin	53 (52.1)
Tobramycin	58 (47.9)
Trimethoprim-sulfamethoxazole	114 (94.2)

Data are *n* (%).

Supplementary Table 2: Antibiotics used within the initial 4 weeks of therapy for 125 solid organ transplant patients with nocardiosis

	Non-disseminated (N=102)	Disseminated (N=33)	Total (N=125)
Number of antibiotics, mean (SD)	2.0 (0.7)	2.4 (0.7)	2.1 (0.8)
Number of active antibiotics, mean (SD) <sup>a</sup>	1.7 (0.7)	2.0 (0.7)	1.8 (0.8)
≥ 2 initial antibiotics	66 (71.7)	31 (93.9)	97 (77.6)
≥ 2 initial active antibiotics <sup>a</sup>	49 (55.7)	25 (75.8)	74 (61.2)
Sulfa antibiotics	62 (67.4)	30 (90.9)	92 (73.6)
- TMP-SMX	59 (64.1)	26 (78.8)	85 (68.0)
- Sulfadiazine	3 (3.3)	4 (12.1)	7 (5.6)
Carbapenem	27 (29.3)	19 (57.6)	46 (36.8)
- Imipenem	14 (15.2)	12 (36.4)	26 (20.8)
- Meropenem	13 (14.1)	7 (21.2)	20 (16.0)
Fluoroquinolone	22 (23.9)	6 (18.2)	28 (22.4)
- Ciprofloxacin	7 (7.6)	2 (6.1)	9 (7.2)
- Levofloxacin	3 (3.3)	0 (0.0)	3 (2.4)
- Moxifloxacin	12 (13.0)	4 (12.1)	16 (12.8)
Macrolide	9 (9.8)	2 (6.1)	11 (8.8)
- Azithromycin	3 (3.3)	2 (6.1)	5 (4.0)
- Clarithromycin	6 (6.5)	0 (0.0)	6 (4.8)
Amikacin	2 (2.2)	1 (3.0)	3 (2.4)
Amoxicillin-clavulanate	9 (9.8)	0 (0.0)	9 (7.2)
Ceftriaxone	13 (14.1)	3 (9.1)	16 (12.8)
Doxycycline	2 (2.2)	0 (0.0)	2 (1.6)
Linezolid	14 (15.2)	11 (33.3)	25 (20.0)
Minocycline	24 (26.1)	6 (18.2)	30 (24.0)
Tigecycline	1 (1.1)	0 (0.0)	1 (0.8)

Data are n (%) unless otherwise specified.

Abbreviations: SD, standard deviation; TMP-SMX, trimethoprim-sulfamethoxazole.

<sup>a</sup>n = 121, excluding 4 patients with non-disseminated nocardiosis whose isolate was unable to grow on susceptibility media.